We would love to hear your thoughts about our site and services, please take our survey here.
I’m very pleased that we’re moving into all possible areas to generate future revenues ,
I also love the move into the veterinary sector and potential huge revenue returns in the near term.
Very interesting proactive one to one with investors presentation.
To be fair they’re doing exactly what they intended to do this year and more.
Great listen.
https://www.google.com/search?q=proactive+investor+fusion+antibodies+plc&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:14b5e405,vid:IAvbf90GgvQ,st:0
Credit
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the receipt of an R&D tax credit from HMRC in respect of the financial year ended 31 March 2023, relating to work performed on the development and optimization of the OptiMAL® platform, as well as other R&D projects in bioinformatics, antigen design and cell culture. The value of the tax credit is in line with expectations at almost £280k, which reflects the Company's continued investment in R&D projects that maintain Fusion at the forefront of technology in the antibody market. The technologies have been well received by partners and potential partners with the OptiMAL® platform notably undergoing validation through an agreement with the National Cancer Institute in the USA. Fusion will maximise the impact of the tax credit with the generation of revenue streams from the R&D projects that were supported.
Adrian Kinkaid, CEO of Fusion, said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."
Just the beginning of the turnaround and already this year we’ve seen two contracts and a collaboration , partnership with the NCI, National Cancer institute in the US.
Some going in Less than three months.
This year is going to be transformational for the company and for us shareholders .
Revenue will follow not far behind.
Strong buy 100 percent.
Any of these?
Something big as they stated it’s a leading global provider of antibodies.
https://blog.citeab.com/who-are-the-leading-research-antibody-market-suppliers/
Ready for a good recovery as FAB has diversified into so many areas of interest and with huge potential also.
I also like the fact that we’ve move into the veterinary sector where there’s an amazing opportunity to increase revenue massively.
Also to be partners with the NCI is a huge milestone for the company and should bring FAB into the limelight’
Just about to begin here.
Mitchell Ho, Ph.D., Deputy Chief, Laboratory of Molecular Biology and Director of the Antibody Engineering Program, Center for Cancer Research, NCI commented: " NCI will test the OptiMAL (R) platform for the discovery of novel antibodies to cancer targets and also SARS-CoV-2. We have a particular interest in Mammalian Cell Display as a discovery engine and look forward to using this in NCI."
Richard Buick, CSO of Fusion, commented: " The expertise and experience of Dr. Ho and his colleagues make NCI an ideal partner for validation of the Optimal (R) library and mammalian cell display technology. I look forward to the collaboration and working closely with the National Cancer Institute."
Definitely the volume has picked up a lot just lately,
I’m very confident in this company and after a disappointing 2023, it looks like 2024 is going to be a very lucrative year for the company.
Watch this space.
Good to be in here.
Mkcap only 4m , this will move very fast on the next news as so many things going on in the background,
This year will see revenues flying in and so will the sp.
Interesting and very positive investors conference.
https://www.google.com/search?q=proactive+investor+fusion+antibodies+plc&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:14b5e405,vid:IAvbf90GgvQ,st:0
I expecting a good day, so undervalued that I can’t buy enough of these.
Very positive encouraging outlook from the proactive one to one investor conference.
https://www.google.com/search?q=proactive+investor+fusion+antibodies+plc&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:14b5e405,vid:IAvbf90GgvQ,st:0